66 results about "Budesonide" patented technology

The invention discloses a capsule medicament for endoscopic treatment of ulcerative colitis and a preparation method thereof, and belongs to the technical field of biological medicine, the capsule medicament is composed of a capsule matrix and a drug matrix; by adopting a dual control mechanism of an enteric layer coating and a pH response layer coating, accurate release of a medicine at a colon diseased region is ensured, medicine waste of the stomach and the small intestine is reduced, the medicine concentration at a focus is improved, mesalazine or budesonide is combined with the composite composition for treatment, inflammatory response is rapidly inhibited, acute symptoms are controlled, and the curative effect is good. A multi-mechanism synergistic treatment mode is adopted, the anti-inflammatory and repairing effects are enhanced, the clinical remission rate and the mucous membrane healing rate are remarkably improved, the pH response layer is dissolved in a colon alkaline environment, and the MMP-9 peptide cross-linking agent is subjected to enzymolysis at an inflammation part, so that the medicine is continuously released at a focus, the administration frequency is reduced, the compliance of a patient is improved, and the curative effect is good. In addition, the spherical gel particles in the medicament can prevent the medicament from being disintegrated too early in the intestinal tract, and the long-acting effect can be maintained.

The invention discloses a degradable antibacterial anti-inflammatory polyurethane sponge and a preparation method thereof. The preparation method of the polyurethane sponge comprises the following steps: preparing caprolactone / lactide copolymer diol by taking epsilon-caprolactone, DL-lactide and 1, 4-butanediol as raw materials under the action of an organic zinc catalyst ZCAT-T50, and then preparing the polyurethane sponge by taking polyethylene glycol and the caprolactone / lactide copolymer diol as raw materials and 4, 4 '-dicyclohexylmethane diisocyanate as a cross-linking agent under the action of the organic zinc catalyst ZCAT-T50. And finally, sequentially adding an organic zinc catalyst ZCAT-T50, a chitosan oligosaccharide emulsion and a budesonide ethanol solution into the polyurethane prepolymer, and carrying out chain extension, foaming and curing, so as to prepare the budesonide-modified polyurethane composite material. The polyurethane sponge prepared by the invention has excellent mechanical properties, degradability and antibacterial and anti-inflammatory properties, is suitable for making medical hemostatic sponge, and has remarkable economic value and social benefit.

The invention provides a special lung atomization therapeutic apparatus for the internal medicine of traditional Chinese medicine, and relates to the technical field of medical instruments, the special lung atomization therapeutic apparatus comprises an atomizer body, an atomization tank, a mist discharging pipe and a connecting pipe, the connecting pipe is inserted into a connecting plug at the bottom end of the atomization tank, and the other end of the connecting pipe is inserted into the air outlet end of the atomizer body; the double-cavity isolation type atomization tank is adopted, and aiming at the scene that salbutamol sulfate, budesonide and the like are compatible but need to be dosed for several times, through the design of the upper-layer independent medicine storage cavity, the lower-layer independent medicine storage cavity and the isolation gas circuit, the medicine can be dosed for several times, and the medicine can be dosed for several times. After the first liquid medicine is atomized, treatment is not required to be interrupted to replace a container or detach an air pipe, and the second medicine can be quickly switched only by cleaning the mask, so that the problems of tedious operation and treatment interruption of fractional atomization of a single medicine tank are solved, and tiny physical and chemical influence possibly caused by advanced mixing of a large amount of liquid medicine is avoided; and meanwhile, the operation time in the emergency scene is remarkably shortened.

1. The name of the design product: packing box (budesonide suspension for inhalation). 2. The use of the design product: for packing medicine. 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo that best shows the design points: design 1 unfolded view. 5. Design 1 is designated as the basic design. 6. Other circumstances that need to be explained: the blank in the elevation view is used for printing bar code or product information such as product batch number, production date, expiration date, etc.

The invention relates to the technical field of medicines, in particular to a budesonide-loaded oral colon targeting delivery system, a preparation method and application. According to the delivery system, budesonide entrapped by Pickering emulsion serves as a core, and a low-ester pectin-calcium ion cross-linked inner layer and a low-ester pectin-chitosan polyelectrolyte composite outer layer are sequentially wrapped on the outer layer; the preparation process is realized by combining an emulsion template method with a layer-by-layer self-assembly technology, the obtained microcapsule is of a uniform spherical structure, the particle size is about 400 microns, and the microcapsule has a double-layer three-dimensional network structure. The delivery system is kept stable in the gastrointestinal environment and releases drugs rapidly only under the colon pH condition, in-vitro simulation experiments show that the drug release rate in the stomach / small intestine stage is lower than 5%, and the drugs are released rapidly in the colon stage. Animal experiments prove that the effect of treating ulcerative colitis is equivalent to that of mesalazine, the toxicity of the whole body is remarkably reduced, the residence time of the medicine at the colon part exceeds 24 hours, and the medicine is not accumulated in a non-target organ.

The invention relates to the technical field of liquid chromatography separation and detection, in particular to a budesonide suspension impurity detection device and method for inhalation, the detection device comprises a liquid chromatograph main body, the liquid chromatograph main body is provided with a power system, a sample introduction system, a chromatographic separation system, a detection system and a data processing system, a chromatographic column mechanism is arranged in the chromatographic separation system, the chromatographic column mechanism comprises a row of chromatographic sub-columns used for chromatographic separation, and a row of cleaned chromatographic sub-columns are distributed on one side of the row of chromatographic sub-columns used for chromatographic separation in parallel. In the cleaning process, the segmented chromatographic columns are washed in turn, the segmented chromatographic columns are short in path, thorough penetrating cleaning can be achieved through small-force washing, and the cleaned chromatographic columns are segmented and put into a chromatographic column queue again, so that the chromatographic columns which are effectively cleaned are subjected to chromatographic separation of the next stage.

The invention discloses an atomizing agent applied to an atomizer and capable of relieving dry cough and a preparation method of the atomizing agent. The effective components comprise the following raw materials: bulbus fritillariae cirrhosae extract, folium eriobotryae extract, radix asteris extract, rhizoma pinelliae extract, radix ophiopogonis extract, herba ephedrae extract, honeysuckle flower extract, radix scutellariae extract, liquorice root extract, dextromethorphan and budesonide. The atomizing agent disclosed by the invention has a good treatment effect on respiratory system disease patients with dry cough without phlegm or less phlegm symptoms, has the effects of moistening lung to arrest cough, reducing phlegm and relieving asthma, resisting inflammation and the like, and can be applied to atomizers.

Disclosed is a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically compatible salt or derivative thereof, and at least 80 wt % of a solid fat or a mixture of different solid fats, based on the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.

The invention belongs to the field of pharmaceutics, and particularly relates to a composition containing budesonide and formoterol, and the composition provided by the invention is in a specific pH range, adopts a specific surfactant addition mode, also adopts moist heat sterilization, and is free of toxic and side effects. The prepared inhalation suspension of formoterol and budesonide has better delivery rate and total delivery amount, better fine particle fraction and smaller particle size distribution, has the advantages of low temperature, short time, strong penetrating power, economy, rapidness and the like compared with dry heat sterilization and moist heat sterilization, and is more suitable for industrial mass production.

The present invention relates to a Budesonide formulation with one or more layers comprising organic acid and Budesonide in the same layer.

The invention provides a budesonide temperature-sensitive gel preparation as well as a preparation method and application thereof, and the budesonide temperature-sensitive gel preparation is mainly prepared from the following components: budesonide, poloxamer 407, poloxamer 188, propylene glycol, hydroxypropyl methyl cellulose, sodium benzoate and pure water. After the budesonide temperature-sensitive gel drug delivery system based on poloxamer 407, poloxamer 188 and hydroxypropyl methylcellulose is applied to a cavity, semi-solid gel can be quickly formed, and strong retention and slow release effects are shown, so that the bioavailability is increased, the formed semi-solid gel can be retained at a drug delivery part and cannot be lost, and the budesonide temperature-sensitive gel drug delivery system is suitable for clinical application. In addition, budesonide can be gradually released, and a remarkable curative effect is shown in short-term clinical application of recurrent chronic sinusitis with nasal polyp.

The application provides a drug delivery system and a preparation method and application thereof, and relates to the technical field of biomedicine.The drug delivery system comprises mesenchymal stem cell exosomes, black phosphorus quantum dots and budesonide.The drug delivery system contains mesenchymal stem cell exosomes, has the functions of immune regulation, anti-inflammation and lung targeting, realizes lung targeted delivery of the black phosphorus quantum dots loaded with budesonide, and realizes precise regulation of lung temperature by utilizing the near-infrared photothermal effect of the black phosphorus quantum dots in asthma for the first time, so that local hyperthermia for allergic asthma is realized.The drug delivery system utilizes the photothermal effect of the black phosphorus quantum dots in the carrier to control the release speed of budesonide, is beneficial to maintaining the optimal drug concentration in the lung, and is expected to reduce the dosage and frequency of medication and reduce the risk of side effects.The application firstly cooperates the mesenchymal stem cell exosomes, local hyperthermia and the immune regulation effect of budesonide for the treatment of allergic asthma.

The invention discloses budesonide enteric-coated sustained-release pellets and a preparation method thereof, and belongs to the technical field of biological medicines. The budesonide enteric-coated and sustained-release pellet sequentially comprises a medicine-containing pellet core, a sustained-release layer and an enteric-coated layer from inside to outside, the drug-containing pill core comprises budesonide, a filler, an adhesive, an acidic agent and a lubricant; the sustained-release layer comprises the following components: a retardant, a plasticizer and an anti-sticking agent; the enteric-coated layer comprises the following components: an enteric-coated material, a plasticizer and an anti-sticking agent. The budesonide enteric-coated sustained-release pellet is prepared by the following steps: preparing budesonide and auxiliary materials into a drug-containing pellet core through an extrusion rolling process, and then coating the drug-containing pellet core with a sustained-release layer and an enteric-coated layer in sequence through a fluidized bed coating, thereby obtaining the budesonide enteric-coated sustained-release pellet. The budesonide enteric-coated and sustained-release pellet cannot be released and absorbed in the stomach, the effect gradually starts after the budesonide enteric-coated and sustained-release pellet reaches the intestinal tract, and the budesonide enteric-coated and sustained-release pellet keeps a proper concentration level in in-vivo blood, so that targeted continuous treatment of inflammatory intestinal diseases is facilitated.

The invention relates to the technical field of conveying devices, in particular to a budesonide suspension blowing, filling and sealing visual inspection conveying system which comprises a closed machine room and a visual inspection module arranged in the closed machine room, and a first conveying track and a second conveying track are further arranged in the closed machine room. A sliding channel is arranged between the first conveying track and the second conveying track; according to the visual inspection conveying system for the budesonide suspension after blowing, filling and sealing, turnover can be completed in the conveying process of the budesonide suspension packaging product, and therefore the visual inspection module can conduct visual inspection on the front face and the back face of the budesonide suspension packaging product conveniently.

Methods and compositions relate to managing chimeric antigen receptor T (CAR T) cell therapy-associated diarrhea in human subjects undergoing such therapy for colorectal cancer (CRC) are disclosed. The CAR T cells target a CRC-associated antigen, such as Guanylate Cyclase C (GCC) or Carcinoembryonic Antigen (CEA). The methods comprise administering a prophylactic regimen to the subject post-infusion of CAR T cells. This regimen includes agents such as vedolizumab, infliximab, or prophylactic budesonide. Subjects are monitored for diarrhea development and severity based on predefined clinical criteria, including stool frequency or stool volume. The methods may further involve a tiered therapeutic algorithm for treating occurring diarrhea, potentially utilizing corticosteroids or antithymocyte globulin (ATG). These approaches aim to reduce the incidence, duration, and severity of CAR T induced diarrhea, thereby improving patient safety and treatment tolerability.

The present application relates to the technical field of medicine, and in particular to a budesonide-loaded oral colon-targeted delivery system, a preparation method and application. The delivery system takes Pickering emulsion-encapsulated budesonide as the core, and is sequentially coated with a low-ester pectin-calcium ion crosslinked inner layer and a low-ester pectin-chitosan polyelectrolyte complex outer layer. The preparation process is realized by combining an emulsion template method with layer-by-layer self-assembly technology. The obtained microcapsules have a uniform spherical structure, a particle size of about 400 μm, and a double-layer three-dimensional network structure. The delivery system remains stable in the gastrointestinal environment, and only releases drugs rapidly under colon pH conditions. In vitro simulation experiments show that the drug release rate is less than 5% in the stomach / small intestine stage, and is rapidly released in the colon stage. Animal experiments confirm that the effect of treating ulcerative colitis is equivalent to that of mesalamine, while the systemic toxicity is significantly reduced, the drug retention time at the colon site is more than 24 hours, and there is no accumulation in non-target organs.

The invention relates to the technical field of Avicel content detection, and discloses a method for detecting the content of Avicel in budesonide nasal spray, which comprises the following steps: mixing diphenylamine, glacial acetic acid and concentrated hydrochloric acid, uniformly stirring to obtain a derivatization reagent, and mixing the derivatization reagent with a detection aid to obtain a composite derivatization reagent; the preparation method comprises the following steps: uniformly mixing a budesonide nasal spray and a solvent, heating and dissolving until the mixture is completely clarified, cooling to room temperature, and adding deionized water for diluting to obtain a budesonide nasal spray solution; mixing the budesonide nasal spray solution with a composite derivatization reagent, carrying out a derivatization reaction, cooling to room temperature to obtain a to-be-detected sample solution, and determining the absorbance of the to-be-detected sample solution by adopting an ultraviolet visible light spectrophotometric method; and recording the Avicel content according to a linear equation of the absorbance and the Avicel concentration. The method has the advantages of high accuracy, high sensitivity, strong specificity and good linearity and accuracy.

The present invention provides a method of treating IgA nephropathy, said method comprising: (i) identifying a pharmaceutically acceptable composition intended for treating IgA nephropathy comprising budesonide and one or more pharmaceutically acceptable excipients providing modulated release of said budesonide following administration to the gastrointestinal tract, said composition being in a standard in vitro USPlt; 711gt, 711gt; in a dissolution test in European Pharmacopoeia 2.9. 3, dissolution equipment using a second method (paddle method) according to the test meets the following requirements; (a) the composition satisfies the requirement that no more than about 10% of the budesonide is released into the dissolution medium within about 120 minutes when the dissolution medium is aqueous and has a pH of about 1.2; (b) the composition satisfies the requirement that no more than about 10% of the budesonide is released into the dissolution medium within about 30 minutes when the dissolution medium is aqueous and has a pH of about 6.8; and (c) the composition satisfying the requirement that at least about 70% of the budesonide is released into the dissolution medium within about 120 minutes when the dissolution medium is aqueous and has a pH of about 6.8; (ii) wherein said method comprises the step of administering said composition to a patient suffering from IgA nephropathy in need of said treatment.

The invention provides a method for detecting impurities in budesonide, and belongs to the technical field of drug detection.The construction method comprises the steps that budesonide is used for preparing a test solution, then gas chromatography detection is conducted, and a chromatogram is obtained so as to detect the impurities in budesonide. As the micromolecular aldehyde substance is a genotoxic impurity of budesonide, the medication safety of budesonide can be better guaranteed by effectively detecting and controlling the micromolecular aldehyde substance, the invention constructs the method for detecting the impurity in budesonide, and the technical blank of detection of the micromolecular aldehyde substance in budesonide is well solved.

The invention discloses a budesonide-loaded ginseng vesicle delivery system and a construction method and application thereof, and belongs to the technical field of plant-derived nano-drug delivery systems. According to the delivery system, nano-vesicles from ginseng are taken as carriers, and budesonide is entrapped to form a BUD-coated GDNPs compound. The delivery system can synergistically enhance the anti-inflammatory effect of budesonide, significantly alleviate airway inflammation of asthma model animals, reduce side effects such as blood glucose disorder and the like caused by high-dose budesonide, and has excellent biological safety. The delivery system provided by the invention can be used for clinical treatment of asthma, is especially suitable for patients who need to use glucocorticoid for a long time, solves the technical problems of low bioavailability and obvious side effects of traditional budesonide, and has important clinical application value and industrialization prospect.

The invention belongs to the technical field of drug detection, and relates to a method for detecting drug particle size distribution of a budesonide suspension preparation. Uniformly mixing an extraction solvent with the budesonide suspension preparation; carrying out solid-liquid separation on the uniformly mixed solution; re-dispersing the solid after solid-liquid separation, and carrying out particle size detection on the solid; wherein the extraction solvent is an ammonia solution of tetraamminecopper, and the ammonia solution contains poloxamer 407 and saturated budesonide. The detection method provided by the invention can realize high-extraction-rate and high-precision particle size analysis of the bulk drugs in the budesonide suspension preparation.

Disclosed are methods to treat patients with AFib by monitoring their heart rhythm to determine the presence and / or the number of episodes of long duration AFib, and optionally the extent of AFib burden. Patients who meet threshold requirements are qualified for the treatment of AFib with a dosage of budiodarone. Patient monitoring is continued in order confirm that the patient is and remains responsive to budiodarone therapy including dose adjusting the patient to achieve such therapy. Subsequently, monitoring is continued to confirm that the patient remains responsive. These methods allow for treatment of the AFib and, correspondingly, reduce or delay the risk of stroke and / or congestive heart failure in the treated patient.

The invention relates to application of an activating agent in promotion of uranium element discharge. Specifically, the activating agent is prepared from rifampicin, erythromycin, progesterone, aldosterone, bilirubin, cholate vinblastine, doxomicin, adriamycin, paclitaxel, bosentan, ambrisentan, digoxin, verapamil, tonavir, amprenavir, indinavir, hypericum perforatum juice, curcumin, atorvastatin beclomethasone, budesonide, divaricasone carbamazepine and caffeine. And phenytoin. The use dosage of the activating agent is 10 to 60 mg / kg. According to the method, the accumulation amount of uranium in important organs such as bones and kidneys can be remarkably reduced, so that the potential toxic influence on the key organs is reduced.

This invention provides ACE2 expression inhibitors and their application in ACE2-mediated diseases. It uses human RXRα as a target protein for virtual drug screening and employs computer molecular docking technology to screen compounds with high affinity for the human RXRα receptor. Combined with cell experiments, it screens compounds that inhibit ACE2. The ACE2 expression inhibitors are at least one of ten drugs selected from ursolic acid, phlorizin, resveratrol, triamcinolone, budesonide, fluticasone propionate, vitamin D2, vitamin D3, calcitriol, and alfacalcidol. The ACE2 inhibitors screened by this invention can serve as targeted drugs for ACE2-mediated diseases, providing more drug options for the prevention or treatment of these diseases.

The present invention relates to salts of budesonide 21-phosphate with β2 adrenergic agonists, preferably with formoterol, pharmaceutical compositions containing the same and the use thereof in the treatment of respiratory inflammatory pathologies, obstructive pathologies and allergen-induced airway dysfunctions. The invention further relates to the process for preparing said salts.

The application discloses a budesonide nasal spray containing manganese ions, which comprises budesonide, water, a suspending agent, and one or more of a surfactant, an osmotic pressure regulator, a chelating agent and a pH regulator, and further comprises an antibacterial agent, potassium sorbate, and an antibacterial synergist, an organic or inorganic salt of divalent manganese ions. The budesonide nasal spray containing manganese ions can improve the bacteriostatic capacity of potassium sorbate on bacteria Sa and fungi Ca by using 0.05-4 ppm manganese ions, and even if the amount of potassium sorbate is as low as 0.06%, the bacteriostatic efficacy can still meet the A standard of the bacteriostatic efficacy inspection method in the Chinese Pharmacopoeia, thereby greatly improving the microbial guarantee level. The results of an accelerated test show that the viscosity of the solution does not change obviously with the increase of the storage time, indicating that the manganese ions also have the effect of stabilizing the solution viscosity.

The application discloses a preparation method of inhalation budesonide superfine crystal with adjustable particle size; the preparation method comprises the following steps: (1) dispersing and dropping budesonide solution A into a deep cold environment with a temperature of-100 to-200 DEG C, and rapidly solidifying the liquid drops into spherical composite particles; (2) under the action of stirring, adding the solidified spherical composite particles in the step (1) into an aqueous solution containing an emulsifier with a temperature of-5 DEG C to 15 DEG C, and obtaining budesonide superfine crystal. The particle size of the budesonide superfine crystal can be effectively adjusted by changing the concentration of the solution A; the obtained superfine crystal product is an ellipsoid with uniform particle size, a roundness value of 0.6 to 1.0, a CV value of 20% to 30%, an average particle size range of 1 to 10 microns, and a unique crystal form; the product is suitable for being developed into an inhalation administration dosage form, especially a dry powder inhalation agent; the process is stable, does not need a post-granulation process such as airflow crushing, is energy-saving and environment-friendly, and can realize large-scale preparation and production.

The present invention provides for a method of treatment of IgA nephropathy, which method comprises:(i) identifying a pharmaceutically acceptable composition intended to treat IgA nephropathy comprising budesonide and one or more pharmaceutically-acceptable excipients that provide for a modified release of said budesonide after administration to the gastrointestinal tract, which composition fulfils the following requirements in a standard in vitro USP<711> / Ph.Eur. 2.9.3 dissolution test using a dissolution apparatus according to Apparatus 2 (Paddle Apparatus) of said test;(a) the composition fulfils the requirement that no more than about 10% of the budesonide is released into the dissolution medium within about 120 minutes, when the dissolution medium is aqueous and has a pH of about 1.2;(b) the composition fulfils the requirement that no more than about 10% of the budesonide is released into a pharmaceutically-relevant dissolution medium within about 30 minutes; and(c) the composition fulfils the requirement that at least about 70% of the budesonide is released into the pharmaceutically-relevant dissolution medium within about 120 minutes;(ii) wherein the method comprises the step of administering said composition to a patient with IgA nephropathy in need of said treatment.

The present invention provides a method of treating IgA nephropathy, the method comprising: (i) identifying a pharmaceutically acceptable composition intended for treating IgA nephropathy comprising budesonide and one or more pharmaceutically acceptable excipients providing modulated release of the budesonide following administration to the gastrointestinal tract, the composition comprising budesonide and one or more pharmaceutically acceptable excipients in a standard in vitro dissolution test, the one or more excipients comprising budesonide and one or more pharmaceutically acceptable excipients comprising budesonide and one or more pharmaceutically acceptable excipients comprising budesonide and one or more pharmaceutically acceptable excipients comprising budesonide and one or more pharmaceutically acceptable excipients comprising budesonide; the following requirements are met; (a) when the dissolution medium is aqueous and has a pH of about 1.2, no more than about 10% of the budesonide is released into the dissolution medium within about 120 minutes; (b) a requirement for no more than about 10% of the budesonide to release into the dissolution medium within about 30 minutes when the dissolution medium is aqueous and has a pH of about 6.8; and (c) a requirement for release of at least about 70% of the budesonide into the dissolution medium within about 120 minutes when the dissolution medium is aqueous and has a pH of about 6.8; (ii) a step of administering said composition to a patient suffering from IgA nephropathy in need of said treatment.